Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/23/2025

Combination Therapy with Repatha and Rosuvastatin

Monitoring and Safety Recommendations

  • The American College of Cardiology recommends monitoring for muscle-related symptoms (pain, tenderness, weakness) at each clinical visit, especially if accompanied by fever or malaise, as this remains a class effect of statin therapy 1
  • The American Heart Association suggests checking creatine kinase (CK) levels only if muscle symptoms develop during therapy—baseline CK is not mandatory but may be considered in high-risk patients 2
  • Consider baseline and periodic liver function tests due to potential hepatotoxicity with statins, though this is not specific to the combination with evolocumab, as recommended by the American Association for the Study of Liver Diseases 1

Drug Interactions and Precautions

  • The American Heart Association advises avoiding combining rosuvastatin with cyclosporine (limit rosuvastatin to 5 mg daily if combination is necessary) or gemfibrozil (limit rosuvastatin to 10 mg daily if gemfibrozil must be used), as these agents significantly increase rosuvastatin exposure through OATP1B1 inhibition, with a strength of evidence level of I (high-quality evidence) 3, 4
  • Exercise caution when rosuvastatin is combined with certain hepatitis C antivirals (sofosbuvir/ledipasvir), as ledipasvir inhibits hepatic OATP and may significantly increase rosuvastatin concentrations, increasing myopathy risk, according to the American Association for the Study of Liver Diseases 5